JAFZA and UAE gov. team up to boost pharma logistics

UAE Ministry of Health & Prevention partners with Jafza to develop pharmaceutical sector.
The Memorandum was signed at Jafza head office by Dr. Amin Hussein Al Amiri, assistant under secretary of Public Health and Licensing Policy at the Ministry of Health and Protection and Mohammed Al Muallem, CEO Jafza and senior vice president and general manager of DP World, UAE Region.
The Memorandum was signed at Jafza head office by Dr. Amin Hussein Al Amiri, assistant under secretary of Public Health and Licensing Policy at the Ministry of Health and Protection and Mohammed Al Muallem, CEO Jafza and senior vice president and general manager of DP World, UAE Region.

Share

SEE ALSO: Analysis: Middle East pharmaceutical logistics

SEE ALSO: Pharma giants turn to Swisslog for intralogistics

SEE ALSO: Emirates SkyPharma hopes for boost from India

The UAE Ministry of Health and Prevention and Jafza have signed a Memorandum of Understanding (MoU) for the development of the healthcare and pharmaceutical sector in the country.

The Memorandum was signed at Jafza head office by Dr. Amin Hussein Al Amiri, assistant under secretary of Public Health and Licensing Policy at the Ministry of Health and Protection and Mohammed Al Muallem, CEO Jafza and senior vice president and general manager of DP World, UAE Region.

Under the agreement, Jafza will develop details for the licensing of pharmaceutical factories within the Free Zone and help them promote public health.

The Ministry will approve licenses for existing factories based on the industrial license issued by Jafza, regardless of the nationality of their owners.

Factories need to register their products and declare whether they are for export or distribution. For use in the UAE, companies will need to obtain a medical warehouse license.

Both organisations will exchange knowledge and remove any barriers to the development of the pharmaceutical sector in the Free Zone. They will also review the process of obtaining approvals and permits from the Ministry, enabling Jafza to attract more foreign investment in the sector.

RELATED: COMMENT: Quality management in pharmaceuticals

RELATED: Emirates SkyCargo launches SkyPharma centre at DXB

The agreement is part of Jafza’s efforts to enhance the healthcare sector by providing the environment for companies to grow and establish ‘Made in Dubai’ pharmaceutical products, using Jebel Ali’s infrastructure to access regional and international markets. 

“This is a major step forward in efforts to raise the competitiveness of the pharmaceutical industry in the country,” said DP World group chairman and CEO, Sultan Ahmed bin Sulayem. “It is also a key part of the Dubai 2021 Plan, aimed at transforming Dubai into a regional hub for medical tourism as the country prepares for the post-oil era.”

“The ultimate aim is to manufacture high quality medicines and healthcare products in Dubai comparable to those around the world with our focus on boosting investment in research and development, and attracting qualified professionals,” he added.

Dr. Amin Al Amiri said the agreement builds on cooperation between federal and local government institutions to promote a legislative and investment environment in keeping with international best practice.

The UAE aims to become a global hub for international pharmaceutical companies and to encourage them to set up factories here. 

There are 54 international pharmaceutical companies already present in the free zone which is expected to rise to over 75 by 2021, with investments of up to AED 2 billion annually.

RELATED: Keeping pharmaceuticals at the right temperature

RELATED: Jafza's FMCG and pharmaceutical trade on the rise

The UAE currently has 17 pharmaceutical factories with 34 expected by 2021.

The plan is to secure medical supplies and provide medicines for patients, especially those suffering from chronic diseases as well as to ensure the sustainability of the pharmaceutical supply chain and capacity of the medical sector.

In 2016, the market value of drugs in the UAE amounted to AED 9.61 billion. By 2020, spending on medicine is expected to reach AED 13.13 billion and by 2025 AED 21.74 billion, driven by population growth, changing morbidity and the use of modern medicines such as biotechnology drugs.

Multinational companies in the healthcare and pharmaceutical sector are currently based in Jafza, such as Johnson & Johnson, Colgate, Roche, Sanofi, GlaxoSmithKline and Quest Vitamins.

Most Popular